Off-Patent Drugs Get UK Spotlight, But Picture Is Still ‘Nuanced’

HTA Body NICE Needs ‘Radical’ Change To Suit Generics & Biosimilars

 
• By Urtė Fultinavičiūtė
  
Mark Samuels, BGMA CEO
Mark Samuels leads Medicines UK, which represents generics and biosimilars firms (Medicines UK)

More from Interviews

More from Pink Sheet